Mainline Biosciences (Shanghai) Co. Ltd. has described peptide-drug conjugates consisting of peptide targeting somatostatin receptors covalently bound to cytotoxic agents through a linker reported to be useful for the treatment of cancer.

Researchers at Cimplrx Co. Ltd. and Samjin Pharmaceutical Co. Ltd. have identified ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (ENPP1) inhibitors reported to be useful for the treatment of cancer, hypophosphatemia, osteoarthritis, cystic fibrosis, type 2 diabetes, Alzheimer’s disease, and viral and bacterial infections.

Genzyme Corp. (Sanofi Genzyme) has divulged emopamil-binding protein (EBP) inhibitors reported to be useful for the treatment of multiple sclerosis, transverse myelitis, neuromyelitis optica, optic neuritis and Guillain-Barré syndrome.

Scientists at Beijing Wehand-Bio Pharmaceutical Co. Ltd. and Institute of Materia Medica Chinese Academy of Medical Sciences & Peking Union Medical College have synthesized phthalazinone compounds with neuroprotective effects reported to be useful for the treatment of hemorrhagic and ischemic stroke.

Syndax Pharmaceuticals Inc. has disclosed extended purine tricyclic and bicyclic nucleosides as prodrugs reported to be useful for the treatment of viral infections.

Biocryst Pharmaceuticals Inc. has described kallikrein 5 (KLK5; KLK-L2) inhibitors reported to be useful for the treatment of allergy, asthma, cancer, conjunctivitis, dermatological disorders, gastrointestinal conditions, inflammatory disorders and rhinitis, among others.

West Pharmaceutical Services Inc. has divulged pyrazolopyridine-containing compounds reported to be useful as DNA-dependent protein kinase (DNA-PK) inhibitors.

Convelo Therapeutics Inc. and Genentech Inc. have identified lanosterol 14α-demethylase (CYP51A1; CYP51) inhibitors reported to be useful for the treatment of multiple sclerosis, encephalomyelitis, optic neuritis, schizophrenia, amyotrophic lateral sclerosis, Alzheimer’s disease, Parkinson’s disease and Huntington’s disease, among others.

Kinnate Biopharma Inc. has synthesized mitogen-activated protein kinase kinase (MAP2K; MEK; MAPKK) inhibitors reported to be useful for the treatment of cancer.

Arrepath Inc. has disclosed UDP-2,3-diacylglucosamine hydrolase (LpxH; bacterial) inhibitors reported to be useful for the treatment of gram-negative bacterial infections.